Lifestyle Asset Management Inc. Trims Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Lifestyle Asset Management Inc. cut its stake in United Therapeutics Co. (NASDAQ:UTHR) by 6.9% during the 1st quarter, HoldingsChannel reports. The fund owned 4,281 shares of the biotechnology company’s stock after selling 318 shares during the period. Lifestyle Asset Management Inc.’s holdings in United Therapeutics were worth $983,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Rise Advisors LLC acquired a new stake in shares of United Therapeutics during the 1st quarter valued at approximately $32,000. GAMMA Investing LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $43,000. Janiczek Wealth Management LLC lifted its position in shares of United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares during the last quarter. Blue Trust Inc. grew its position in shares of United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its position in shares of United Therapeutics by 31.2% during the 4th quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 138 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on UTHR. Oppenheimer lifted their target price on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, May 2nd. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $312.22.

United Therapeutics Price Performance

United Therapeutics stock traded down $6.01 during trading hours on Wednesday, hitting $311.04. 281,294 shares of the company traded hands, compared to its average volume of 497,971. The firm’s 50-day simple moving average is $279.61 and its two-hundred day simple moving average is $245.36. The firm has a market cap of $13.80 billion, a P/E ratio of 14.71, a P/E/G ratio of 1.40 and a beta of 0.55. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $325.00. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.86 earnings per share. As a group, analysts forecast that United Therapeutics Co. will post 24.73 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $233.27, for a total transaction of $3,499,050.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,325.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $320.45, for a total transaction of $1,153,620.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $41,658.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $233.27, for a total value of $3,499,050.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,325.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 129,944 shares of company stock valued at $33,580,082. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.